

LIMITED REVIEW REPORT

*To the Board of Directors
Anglo-French Drugs & Industries Limited,
41, 3rd Cross, V Block, Rajajinagar,
Bangalore – 560 010.*

We have Reviewed the accompanying statement of Unaudited financial results of Anglo-French Drugs & Industries Limited for the quarter ended 30th June 2017 attached herewith ,being submitted by the company pursuant to requirements of Regulation 33 of the SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5th 2016 . This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act,2013,read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations & Disclosure Requirements)Regulations,2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5th 2016 ,including the manner, in which it is to be disclosed, or that it contains any material misstatement.

We have not audited or reviewed the statement and other financial information for the quarter ended June 30th, 2016 which have been presented solely based on the information compiled by the management.

**For RAY & RAY
Chartered Accountants**

Place: Bangalore
Date:


MRINAL KANTI BANERJEE
Partner
Membership No. 051472
Firm Registration No.301072E

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

REGD. OFF: 41, 3rd CROSS, SSI AREA, V BLOCK, RAJAJINAGAR, BANGALORE - 560 010

Un-Audited Financial Results for the quarter ended 30th June 2017 (Standalone)

(Rs in Laacs, except No of equity shares & Earning per share)

PARTICULARS	3 months ended (30/06/2017) (Un-Audited)	Corresponding 3 months ended in the previous year (30/06/2016) (Un- Audited)
1. Income from Operations		
(a) Net Sales / Income from Operations (Inclusive of Excise Duty)	1876	3049
(b) Other Operating Income	5	25
Total Income from operations (Net)	1881	3074
2. Expenses		
a. Cost of Material, components & stores Consumed	676	1159
b. Purchase of Stock in Trade	392	727
c. Changes in Inventories of Finished goods, work in progress & Stock in Trade	81	(213)
d. Employee Benefit Expenses	590	567
e. Depreciation and Amortisation Expenses	48	42
f. Other expenditure	866	842
Total Expenses	2653	3124
3. Profit /(Loss) from Operations before Other Income, Finance Costs and Exceptional Items (1-2)	(772)	(50)
4. Other Income	7	9
5. Profit /(Loss) (from Ordinary activities before Finance Costs and Exceptional items (3+4))	(765)	(41)
6. Finance Costs	88	80
7. Profit /(Loss) from Ordinary activities after Finance Costs but before Exceptional Items (5-6)	(853)	(121)
8. Exceptional Items	0	0
9. Profit(+)/Loss(-) from Ordinary Activities before Tax (7+8)	(853)	(121)
10. Tax Expenses	0	0
11. Net Profit(+)/Loss(-) from Ordinary Activities after Tax (9-10)	(853)	(121)
12. Extraordinary Item (net of tax expenses)	0	0
13. Net Profit(+)/Loss(-) for the period	(853)	(121)
14. Other Comprehensive Income		
a)(i) Items that will not be reclassified to profit & Loss	(6)	(1)
(ii) Income tax on items that will not be reclassified to profit or loss		
b)(i) Items that will be reclassified to profit & Loss		
ii) Income tax on items that will be reclassified to profit or loss		
Total Other Comprehensive Income	(6)	(1)
Total Comprehensive Income(13+14)	(859)	(122)
15. Paid up equity share capital (Face Value ` 10/-each)	116	116
16. Other Equity	729	1451
17. Earning per share (in Rs.)		
a) Basic and Diluted before Extraordinary Item	(73.85)	(0.09)
b) Basic and Diluted after Extraordinary Item	(73.85)	(0.09)

Notes:

1 The company has adopted Indian Accounting Standards prescribed under Section 133 of the Companies Act,2013 (Ind AS) from April 1 2017 and all the periods presented in the financial results & other financial information has been prepared in accordance with recognition & measurement principles laid down in Ind AS & discloses information required to be disclosed under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations ,2015,read with SEBI circular no. CIR/CFD/FAC/62/2016 dated July 5,2016

2 The company has also prepared a reconciliation of the net profit for the corresponding periods under the previously applicable Generally Accepted Accounting Principles("previous GAAP) with the total comprehensive income as reported in these financial results under Ind AS.The net profit reconciliation for the quarters ended 30th June 2017 & 30th June 2016 for the financial results are presented below:

Rs. in lakhs		
3 Reconciliation of the Net Profit/(Loss) reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:	Quarter ended 30.6.2017	Quarter ended 30.6.2016
Net Profit /(Loss)as per previous GAAP(Indian GAAP)	(857.69)	(123.65)
Actuarial loss on employee defined benefit plan recognised in Other Comprehensive Income as per Ind AS 19	5.46	2.42
Fair Valuation of Financial Assets & Liabilities as per Ind AS 109	(0.39)	(0.13)
Net Profit/(Loss) as per Ind AS	(852.62)	(121.36)
Other Comprehensive Income	(5.91)	(1.16)
Total Comprehensive income for the period	(858.53)	(122.52)

4 The Ind AS financial results for the quarter ended 30.6.2016 have been compiled by the management after considering the necessary changes to give a true & fair value of the results in accordance with Ind As. The Ind AS adjustments made in the financial results for the quarter ended 30.6.2016 has not been subjected to any limited review or audit .

5 Disclosure of figures for previous year ended 31st March 2017 & quarter ended 31st March 2017 is not mandatory as per Para 2.6.1(ii) - CIR/CFD/FAC/62/2016 Dated 5th July 2016.

6 The above financial results were taken on record by the Board of Directors in their Meeting held on 12th September 2017

7 The figures in respect of previous period have been regrouped/recast wherever necessary.The statutory auditors have carried out a limited review of the financial statements for the quarter ended 30th June 2017.

Place:Mumbai
Date: 12.09.2017

ANGLO-FRENCH DRUGS & INDUSTRIES LTD



ABHAY KANORIA
CHAIRMAN & MANAGING DIRECTOR